Lecanemab for Treatment of Early Alzheimer Disease

Summary for Physicians

Lecanemab in Early Alzheimer Disease: Clinical Experience and Quality of Life Impact

Clarity AD Phase 3 Trial Overview:

• Evaluated lecanemab, a monoclonal antibody targeting soluble amyloid-β protofibrils, in patients with early Alzheimer disease mild cognitive impairment or mild dementia with confirmed amyloid pathology).

• Demonstrated a statistically significant slowing of cognitive and functional decline over 18 months, as measured by:

• CDR-SB (Clinical Dementia Rating–Sum of Boxes)

• ADAS-Cog14 (Alzheimer Disease Assessment Scale–Cognitive Subscale)

• ADCS-MCI-ADL (Alzheimer Disease Cooperative Study–Activities of Daily Living)

Quality of Life Observations in Practice: While traditional cognitive scales were the primary end points in Clarity AD, improvements and preservation of quality of life are being increasingly observed in clinical settings:

• Slower Decline in Functional Abilities: Patients and caregivers report better retention of independence in activities like managing finances, navigating familiar environments, and engaging in conversations.

• Emotional and Psychosocial Stability: Some patients demonstrate reduced anxiety and frustration linked to cognitive decline; caregivers often note improved mood and engagement.

• Enhanced Caregiver Confidence: Families feel reassured by having an active treatment plan in place, contributing to improved caregiver quality of life and reduced burnout.

• Delayed Progression: While not a cure, lecanemab appears to give patients more time in earlier, higher-functioning stages—impacting planning, autonomy, and daily satisfaction.

Clinical Integration Considerations:

• Baseline Amyloid Confirmation: Required prior to initiation.

• Monitoring for amyloid-related imaging abnormalities: Regular MRI surveillance is necessary to manage potential adverse effects.

• Patient Selection: Best suited for patients in early symptomatic stages with adequate support systems and close clinical monitoring.

• Insurance and Access Barriers: Still evolving, requiring documentation of diagnosis, biomarker status, and ongoing neurologic evaluation.